Posted on March 21st, 2013 by Logan Lafferty
The study examined the progression of 1,098 patients who had their DNA sequenced at the Mayo Clinic and were contacted as many as 15 years later to determine how they were faring…Alnylam, based in Cambridge, Massachusetts, licensed alpha- synuclein technology from the Mayo Clinic and is developing a product that would be delivered directly into the brains of patients.
Additional Coverage: Bloomberg
Bloomberg Businessweek by Michelle Fay Cortez
You must be logged-in to the site to post a comment.